Heart rate, age and the risk of progression to kidney failure in patients with CKD.

J Nephrol

Nephrology, Dialysis and Transplantation Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.

Published: June 2013

Background And Methods: Since heart rate (HR) is a cardiovascular risk factor and a marker of sympathetic activity, we tested the predictive value of HR for progression to kidney failure in a well characterized cohort of 759 patients with stage 2-5 CKD followed up for 29 ± 11 months.

Results: Overall, a total of 244 patients had renal events. In an unadjusted analysis by age tertiles the predictive value of HR for renal events was apparent only in patients in the third age tertile (older than 68 years) but not in those in the first two tertiles indicating effect modification by age of the HR--progression to kidney failure relationship. In a multiple Cox regression model adjusting for potential confounders, a 5 beats/min increase in HR entailed a 16% risk excess (Hazard Ratio = 1.16, P = .004) for renal events in patients in the third age tertile but no excess risk for the same events in patients in the first two tertiles. A statistically significant interaction (P<.001) was also found between age and the risk for renal events associated with proteinuria.

Conclusions: Heart rate is an independent age-dependent effect modifier for progression to kidney failure in CKD patients. This observation generates the hypothesis that high sympathetic activity is a relevant risk factor for adverse renal outcomes in elderly patients with CKD.

Download full-text PDF

Source
http://dx.doi.org/10.5301/jn.5000229DOI Listing

Publication Analysis

Top Keywords

kidney failure
12
renal events
12
heart rate
8
progression kidney
8
patients third
8
third age
8
age tertile
8
events patients
8
patients
6
age
5

Similar Publications

Background: This case report describes a unique presentation of sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) caused by a rare SGPL1 variant, highlighting the diagnostic and management challenges associated with this condition.

Case Presentation: A 2-year-old Iranian female presented with steroid-resistant nephrotic syndrome (NS), primary adrenal insufficiency (AI), growth delay, seizures, and hyperpigmentation. Laboratory evaluation revealed hypoalbuminemia, significant proteinuria, hyperkalemia, and elevated adrenocorticotropic hormone (ACTH) levels.

View Article and Find Full Text PDF

Risk of severe maternal morbidity and mortality among pregnant patients with chronic kidney disease: Renal disease and severe maternal morbidity.

Am J Obstet Gynecol MFM

January 2025

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, Ohio 45267, USA. Electronic address:

Background: Chronic kidney disease is a significant cause of adverse obstetric outcomes. However, there are few studies assessing the risk of severe maternal morbidity and mortality among patients with chronic kidney disease and no studies assessing the association between individual indicators of severe maternal morbidity and chronic kidney disease.

Objective: To evaluate the risk of severe maternal morbidity and mortality among pregnant patients with chronic kidney disease.

View Article and Find Full Text PDF

Background: This study aimed to evaluate the incidence, contributing factors, and clinical outcomes of acquired cystic kidney disease (ACKD) in children undergoing kidney replacement therapy (KRT).

Methods: We conducted a cross-sectional, territory-wide study at the designated pediatric nephrology center in Hong Kong. ACKD was defined as the presence of ≥ 3 cysts in the native kidneys, excluding congenital or hereditary cystic diseases.

View Article and Find Full Text PDF

Purpose: Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations.

Methods: A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone's cardiovascular and renal effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!